FDA News Digest February 24, 2003 ______________________________________________ FDA Completes Initial Rx Manufacturing Regulation Improvements FDA has completed the first steps of an initiative announced last year to modernize the agency's regulation of pharmaceutical manufacturing and product quality. Accomplishments to date include allowing manufacturers to make certain process changes without prior FDA approval, clarifying language used in FDA inspection reports, and focusing agency resources on inspections likely to have the greatest public benefit. Press release: http://www.fda.gov/bbs/topics/NEWS/2003/NEW00872.html Progress report on initiative: http://www.fda.gov/cder/gmp/21stcenturysummary.htm ___________________________________________________________ Online Video Introduces New FDA Office of In Vitro Diagnostics An archived video recording of a Feb. 19 satellite broadcast that introduced FDA's new Office of In Vitro Diagnostic Device Evaluation and Safety is available on FDA's website. In it, key officials discuss advantages the new office can offer manufacturers, what industry can expect from the new office, and what it will expect from industry. http://www.connectlive.com/events/fdaoivd/ ___________________________________________________________ PUBLIC MEETINGS FDA's 2003 Science Forum Now Open for Registration Interested persons can register now for the 9th Annual FDA Science Forum, to be held in Washington, D.C., April 24-25. Open to the public, the forum brings FDA scientists together with industry, academia, consumers, and others to share information about the science-based mission of the agency. Discussion topics for this year's forum include risk assessment and public health initiatives in the wake of 9/11/01. http://www.dcscienceforum.org For a list of upcoming FDA meetings, seminars, and other public events, go to http://www.fda.gov/opacom/hpmeetings.html. __________________________________________________________________ Thanks for subscribing to the FDA News Digest. Our next posting will be March 3. To leave this list at any time, send an e-mail to LISTSERV@LIST.NIH.GOV In the body of the message, write SIGNOFF FDA-NEWSDIGEST-L
